These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 10416595)
21. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693 [TBL] [Abstract][Full Text] [Related]
22. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas. Takahashi M; Ozaki T; Todo S; Nakagawara A Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504 [TBL] [Abstract][Full Text] [Related]
23. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Leone A; Seeger RC; Hong CM; Hu YY; Arboleda MJ; Brodeur GM; Stram D; Slamon DJ; Steeg PS Oncogene; 1993 Apr; 8(4):855-65. PubMed ID: 8384356 [TBL] [Abstract][Full Text] [Related]
24. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)]. Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442 [TBL] [Abstract][Full Text] [Related]
25. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551 [TBL] [Abstract][Full Text] [Related]
26. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847 [TBL] [Abstract][Full Text] [Related]
27. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353 [TBL] [Abstract][Full Text] [Related]
28. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. Nakagawara A; Arima-Nakagawara M; Scavarda NJ; Azar CG; Cantor AB; Brodeur GM N Engl J Med; 1993 Mar; 328(12):847-54. PubMed ID: 8441429 [TBL] [Abstract][Full Text] [Related]
29. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906 [TBL] [Abstract][Full Text] [Related]
30. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma. Amler LC; Schürmann J; Schwab M Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178 [TBL] [Abstract][Full Text] [Related]
31. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516 [TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931 [TBL] [Abstract][Full Text] [Related]
33. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322 [TBL] [Abstract][Full Text] [Related]
34. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Gehring M; Berthold F; Edler L; Schwab M; Amler LC Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602 [TBL] [Abstract][Full Text] [Related]
35. myc gene amplification and expression in primary human neuroblastoma. Slavc I; Ellenbogen R; Jung WH; Vawter GF; Kretschmar C; Grier H; Korf BR Cancer Res; 1990 Mar; 50(5):1459-63. PubMed ID: 2302711 [TBL] [Abstract][Full Text] [Related]
36. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
37. N-myc amplification and cell proliferation rate in human neuroblastoma. Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991 [TBL] [Abstract][Full Text] [Related]
38. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly. Poremba C; Hero B; Goertz HG; Scheel C; Wai D; Schaefer KL; Christiansen H; Berthold F; Juergens H; Boecker W; Dockhorn-Dworniczak B Klin Padiatr; 2001; 213(4):186-90. PubMed ID: 11528552 [TBL] [Abstract][Full Text] [Related]
39. Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features. Ball NS; King PH Clin Cancer Res; 1997 Oct; 3(10):1859-65. PubMed ID: 9815574 [TBL] [Abstract][Full Text] [Related]
40. Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation. Tsuda H; Shimosato Y; Upton MP; Yokota J; Terada M; Ohira M; Sugimura T; Hirohashi S Lab Invest; 1988 Sep; 59(3):321-7. PubMed ID: 3411933 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]